6/17/2019

CURRICULUM VITAE
JERROLD L. BOXERMAN, M.D., Ph.D., F.A.C.R.

Business Address:	Rhode Island Hospital Department of Diagnostic Imaging 593 Eddy Street Providence, RI 02903
Business Telephone Number:	(401) 444-5184
Business Fax Number:	(401) 444-5017
Email Address:	jboxerman@lifespan.org

EDUCATION

Undergraduate:	Massachusetts Institute of Technology Cambridge, MA S.B. (*Electrical Engineering*) June 1989
Graduate:	Massachusetts Institute of Technology Cambridge, MA S.M. (*Electrical Engineering and Computer Science*) June 1989
	Massachusetts Institute of Technology Cambridge, MA Ph.D. (*Medical Engineering*) June 1995
Medical School:	Harvard Medical School Boston, MA M.D. June 1996

POST-GRADUATE TRAINING

Research Fellowship:	The Johns Hopkins Hospital Baltimore, MD Post-doctoral Research Associate Diagnostic Radiology, MRI Division 1996-1997
Residency:	The Johns Hopkins Hospital Baltimore, MD Diagnostic Radiology 1997-2001 (Chief Resident, 2000)

Fellowship: The Johns Hopkins Hospital
Baltimore, MD
Neuroradiology
October 2000-February 2001, July 2001-August 2002

HONORS AND AWARDS

Massachusetts Institute of Technology — Cambridge, MA

1987	Inductee, Tau Beta Pi Engineering Honor Society
1987	Inductee, Eta Kappa Nu Electrical Engineering Honor Society
1989-1992	National Science Foundation Graduate Scholarship

Massachusetts General Hospital, NMR Center — Charlestown, MA

1992, 1994	Johnson & Johnson Research Fellowship
1993	Clement Vaturi Research Fellowship

Harvard Medical School — Boston, MA

1995	Honors in core medicine, medicine sub-internship, surgery, radiology, neurology, and obstetrics and gynecology clerkships

Johns Hopkins Department of Radiology — Baltimore, MD

2000	**Chief Resident**, Diagnostic Radiology

Brown University / Rhode Island Hospital — Providence, RI

2003-2004	**Teacher of the Year**, Diagnostic Radiology Residency Program, Brown University / Rhode Island Hospital
2016	Recognized as a **Fellow, American College of Radiology**

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

2001-Present	American Board of Radiology (Lifetime certificate)
2002-Present	State of Rhode Island, Medical License No. MD10844
2002-Present	State of Massachusetts, Medical License No. 213422
2004	American Board of Radiology, initial Certificate of Added Qualification in *Neuroradiology*
2014	American Board of Radiology, Recertification of Added Qualification in *Neuroradiology*

ACADEMIC APPOINTMENTS

2002-2003	Assistant Professor of Diagnostic Imaging, Clinical Educator Track Alpert Medical School, Brown University

2004-2012	Assistant Professor of Diagnostic Imaging, Teaching Scholar Track Alpert Medical School, Brown University
2012-2019	Associate Professor of Diagnostic Imaging, Teaching Scholar Track Alpert Medical School, Brown University
2019-present	Professor of Diagnostic Imaging, Teaching Scholar Track Alpert Medical School, Brown University

HOSPITAL APPOINTMENTS AND POSITIONS

2001-2002	Practicing Radiologist Johns Hopkins Bayview Medical Center, Baltimore, MD
2001-2002	Practicing Radiologist American Radiology, Baltimore, MD
2002-Present	Attending Neuroradiologist Department of Diagnostic Imaging Rhode Island Hospital, Providence, RI
2002-Present	Attending Radiologist The Miriam Hospital, Providence, RI
2002-Present	Attending Radiologist Women & Infants Hospital, Providence, RI
2015-Present	Attending Radiologist Roger Williams Medical Center, Providence, RI
2015-Present	Attending Radiologist Saint Joseph's Health Services, North Providence, RI

OTHER APPOINTMENTS AND POSITIONS

2004-2011	**Co-Chair** (Greg Sorensen, M.D.), American College of Radiology Imaging Network (ACRIN) Brain / Head and Neck Committee
2005-2007	Associate Residency Program Director, Department of Diagnostic Imaging, Rhode Island Hospital
2006-Present	Member, Medical Advisory Board, Imaging Biometrics, LLC, Milwaukee, WI

2011-Present	**Vice-Chair for Brain** (Chair: Dan Barboriak, M.D.), American College of Radiology Imaging Network (ACRIN) Head and Neck / Neuro Committee
2013-Present	Member, ECOG-ACRIN Scientific Advisory Committee
2014-Present	Member, Jumpstarting Brain Tumor Drug Development Coalition's Imaging Standardization Steering Committee; **Co-chair** of the Perfusion DSC-MRI Working Group
2014-Present	Member, Quantitative Imaging Biomarker Alliance (QIBA) DSC Perfusion Measure Workgroup
2015-Present	Member, GBM International Adaptive Trial Imaging Committee
2018-Present	Member, National Cancer Institute (NCI) Clinical Trials and Translational Research Advisory Committee (CTAC) *ad hoc* Working Group on Glioblastoma

JOURNAL REVIEWER

1999-Present	Reviewer, *Journal of Magnetic Resonance Imaging*
2001-Present	Reviewer, *Magnetic Resonance in Medicine*
2006-Present	Reviewer, *American Journal of Neuroradiology*
2007-Present	Reviewer, *Radiology*
	2011 Editor's Recognition Award, Reviewing with Distinction
2011-Present	Reviewer, *Clinical Neurology and Neurosurgery*
2015-Present	Reviewer, *Neuro-Oncology*

HOSPITAL COMMITTEES

2006-2009	Member, Stroke Center Executive Committee, Rhode Island Hospital
2014-2015	Member, search committee for neuro-oncologist, Department of Neurology, Rhode Island Hospital
2017-Present	Member, Education Committee, Department of Diagnostic Imaging, Rhode Island Hospital
	Primary responsibility: resident applicant interviews

UNIVERSITY COMMITTEES

2006-Present	**Medical Director** and Member of Scientific Advisory Committee, 3T MRI Research Facility, Institute for Brain Science, Brown University (Jerome Sanes, chair)
2012-Present	**Co-chair** for Neuroradiology, Radiology Committee of the Brown University Oncology Group (Howard Safran, chair)
2016-2017	**Member**, Brown Institute for Brain Science committee reviewing BIBS/NPNI New Frontiers Awards (John Davenport, chair)

MEMBERSHIP IN SOCIETIES

1992-Present	International Society, Magnetic Resonance in Medicine (ISMRM)
1997-Present	American Roentgen Ray Society (ARRS)
1997-Present	Radiological Society of North America (RSNA)
2000-Present	American College of Radiology (ACR)
2016	**Awarded Fellow status**
2001-Present	American Society of Neuroradiology (ASNR), **Senior Member**
2006-2008, 2016-Present	Member, research committee Grant reviewer, ASNR Foundation awards
2007-Present	Member, education committee Outstanding presentations subcommittee
2007-Present	Abstract reviewer for annual scientific meeting
2002-Present	Rhode Island Medical Society (RIMS)
2002-Present	Rhode Island Radiology Society (RIRS)
2008-2009	**Secretary**
2009-2010	**Treasurer**
2010-2011	**Vice-President**
2011-2012	**President**
2004-Present	New England Roentgen Ray Society (NERRS)
2005-2007	Association of Program Directors in Radiology (APDR)
2006-2007	Member, Annual Survey Committee
2006-2007	Member, Electronic Communication and Publications Committee
2005-Present	Association of University Radiologists (AUR)
2012-Present	American Society of Functional Neuroradiology (ASFNR)
2015-Present	Member, Clinical Practice Committee
2015-Present	Member, Research Committee
2016-Present	Eastern Neuroradiological Society (ENRS)

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Weisskoff RM, Chesler D, **Boxerman JL**, Rosen BR. Pitfalls in MR measurement of tissue blood flow with intravascular tracers: Which mean transit time? Magn Reson Med 1993; 29(4):553-558. PMID: 8464373.

2. Weisskoff RM, Zuo CS, **Boxerman JL**, Rosen BR. Microscopic susceptibility variation and transverse relaxation: Theory and experiment. Magn Reson Med 1994; 31(6):601-610. PMID: 8057812.

3. **Boxerman JL**, Bandettini PA, Kwong KK, Baker JR, Davis TL, Rosen BR, Weisskoff RM. The intravascular contribution to fMRI signal change: Monte Carlo modeling and diffusion-weighted studies *in vivo*. Magn Reson Med 1995; 34(1):4-10. PMID: 7674897.

4. **Boxerman JL**, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995; 34(4): 555-566. PMID: 8524024.

5. Sorensen AG, Wray SH, Weisskoff RM, **Boxerman JL**, Davis TL, Caramia F, Kwong KK, Stern CE, Baker JR, Breiter H, Gazit IE, Belliveau JW, Brady TJ, Rosen BR. Functional MR of brain activity and perfusion in patients with chronic cortical stroke. AJNR Am J Neuroradiol 1995; 16(9):1753-1762. PMID: 8693971.

6. Lev MH, Kulke SF, Sorensen AG, **Boxerman JL**, Brady TJ, Rosen BR, Buchbinder BR, Weisskoff RM. Contrast-to-noise ratio in functional MRI of relative cerebral blood volume with sprodiamide injection. J Magn Reson Imaging 1997; 7(3):523-527. PMID: 9170037.

7. **Boxerman JL**, Rosen BR, Weisskoff RM. Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies. J Magn Reson Imaging 1997; 7(3):528-537. PMID: 9170038.

8. Bluemke DA, **Boxerman JL**, Atalar E, McVeigh ER. Segmented k-space cine breath-hold cardiovascular MR imaging: I. Principles and technique. AJR Am J Roentgenol 1997; 169(2):395-400. PMID: 9242742.

9. Bluemke DA, **Boxerman JL**, Mosher T, Lima JAC. Segmented k-space cine breath-hold cardiovascular MR imaging: II. Evaluation of aortic vasculopathy. AJR Am J Roentgenol 1997; 169(2):401-407. PMID: 9242743.

10. **Boxerman JL**, Mosher TJ, McVeigh ER, Atalar E, Lima JAC, Bluemke DA. Advanced MR imaging techniques for evaluation of the heart and great vessels. Radiographics 1998; 18(3):543-564. PMID: 9599382.

11. Reeder SB, Faranesh AZ, **Boxerman JL**, McVeigh ER. In vivo measurement of T2* and field inhomogeneity maps in the human heart at 1.5 T. Magn Reson Med 1998; 39(6):988-998. PMID: 9621923.

12. Dennie J, Mandeville JB, **Boxerman JL**, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998; 40(6):793-799. PMID: 9840821.

13. Kawamoto S, Shirai N, Strandberg JD, **Boxerman JL**, Bluemke DA. Nontraumatic osteonecrosis: MR perfusion imaging evaluation in an experimental model. Acad Radiol 2000; 7(2):83-93. PMID: 10730163.

14. Beache GM, Herzka DA, **Boxerman JL**, Post WS, Gupta SN, Faranesh AZ, Solaiyappan M, Bottomley PA, Weiss JL, Shapiro EP, Hill MN. Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circulation 2001; 104(11):214-1217. PMID: 11551869.

15. **Boxerman JL**, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006; 27(4):859-867. PMID: 16611779.

16. Goldman M, **Boxerman JL**, Rogg JM, Noren G. The Utility of Apparent Diffusion Coefficient in Predicting the Outcome of Gamma Knife Treated Brain Metastases Prior to Changes in Tumor Volume: a Preliminary Study. J Neurosurg 2006 Dec; 105(Suppl):175-182. PMID: 18503353.

17. **Boxerman JL**, Hawash K, Bali B, Clarke T, Rogg J, Pal DK. Is Rolandic epilepsy associated with abnormal findings on cranial MRI? Epilepsy Research 2007; 75(2-3):180-185. PMID: 17624735.

18. **Boxerman JL**, Rogg JM, Donahue JE, Machan JT, Goldman MA, and Doberstein CE. Pre-operative MR Evaluation of Pituitary Macroadenomas: Imaging Features that Predict Successful Transsphenoidal Surgery. AJR Am J Roentgenol. 2010 Sep;195(3):720-8. PMID: 20729452.

19. Koo EH, **Boxerman JL**, Murphy MA. Cortical Blindness Following a Near-Drowning Incident. J Neuroophthalmol 2011; 31(4):347-9. PMID: 21775894.

20. **Boxerman JL**, Prah DE, Paulson ES, Machan JT, Bedekar D, Schmainda KM. The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard. AJNR Am J Neuroradiol 2012 33(6):1081-87. PMID: 22322605.

21. Jayaraman MV, **Boxerman JL**, Davis LM, Haas RA, Rogg JM. Incidence of Extrinsic Compression of the Internal Jugular Vein in Unselected Patients Undergoing CT Angiography. AJNR Am J Neuroradiol 2012 33(7):1247-50. PMID: 22322614.

22. Raghavan D, **Boxerman JL**, Rogg JM, Cosgrove R. Glioblastoma Multiforme: Utilization of Advanced MRI Techniques for Preoperative Planning. Med Health RI 2012 Feb;95(2):42-3. PMID: 22474872.

23. **Boxerman JL**, Jayaraman MV, Mehan WA, Rogg JM, Haas RA. Clinical Stroke Penumbra: Use of NIH Stroke Scale as a Surrogate for CT Perfusion in Patient Triage for Intra-arterial MCA Stroke Therapy. AJNR Am J Neuroradiol 2012 33(10):1893-900. **(Selected for AJNR News Digest, March 2016)** PMID: 22627795.

24. Raghavan D, **Boxerman JL**, Jeyapalan S, Rogg JM. Radiation Necrosis of a High-Grade Glioma. Med Health RI 2012 May;95(5):159-60. PMID: 22808637.

25. Jeyapalan S, **Boxerman JL**, Donahue J, Goldman M, Kinsella T, Dipetrillo T, Evans D, Elinzano H, Constantinou M, Stopa E, Puthawala Y, Cielo D, Santaniello A, Oyelese A, Mantripragada K, Rosati K, Isdale D, Safran H. Paclitaxel Poliglumex, Temozolomide and Radiation for Newly Diagnosed High-Grade Glioma: A Brown University Oncology Group Phase II Study. Am J Clin Oncol. 2014 Oct;37(5):444-9. PMID: 23388562.

26. **Boxerman JL**, Paulson ES, Prah M, Schmainda KM. The Effect of Pulse Sequence Parameters and Contrast Agent Dose on Percent Signal Recovery in DSC-MRI: Implications for Clinical Applications. AJNR Am J Neuroradiol 2013 34(7):1364-9. PMID: 23413249.

27. Spader HS, Ellermeier A, O'Muircheartaigh J, Dean III, DC, Dirks H, **Boxerman JL**, Cosgrove GR, Deoni SCL. Advances in Myelin Imaging with Potential Clinical Application to Pediatric Imaging. Neurosurg Focus 2013 34(4):E9. PMID: 23544415.

28. Ratai EM, Zheng Z, Snyder B, **Boxerman JL**, Safriel Y, Gilbert M, Sorensen AG, Barboriak D. Magnetic Resonance Spectroscopy as an Early Indicator of Response to Anti-angiogenic Therapy in Patients with Recurrent Glioblastoma: ACRIN 6677 / RTOG 0625. Neuro Oncol. 2013 Jul;15(7):936-44. PMID: 23645534.

29. Swenson DW, Nickel BJ, **Boxerman JL**, Klinge PM, Rogg JM. Prenatal MRI Characterization of Brainstem Glioma. Pediatr Radiol. 2013 Oct;43(10):1404-7. PMID: 23677423.

30. **Boxerman JL**, Zheng Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP. Early Post-Bevacizumab Progression on Contrast-Enhanced MRI as a Prognostic Marker for Overall Survival in Recurrent Glioblastoma: Results from the ACRIN 6677 / RTOG 0625 Central Reader Study. Neuro Oncol. 2013 Jul;15(7):945-54. PMID: 23788270.

31. Semmineh NB, Xu J, **Boxerman JL**, Delaney GW, Cleary PW, Gore JC, Quarles CC. An efficient computational approach to characterize DSC-MRI signals arising from three-dimensional heterogeneous tissue structures. PLoS One. 2014 Jan 8;9(1):e84764. PMID: 24416281.

32. Shiroishi MS, Castellazzi G, **Boxerman JL (co-first author)**, Essig M, Nguyen TB, Provenzale JM, Enterline DS, Anzalone N, Dorfler A, Rovira A, D'Amore F, Wintermark M, Law M. Principles of T_2*-Weighted Dynamic Susceptibility Contrast MRI Technique in Brain Tumor Imaging. J Magn Reson Imaging. 2015 Feb;41(2):296-313. PMID: 24817252.

33. Chodakiewitz Y, Brown S, **Boxerman JL**, Brody J, Rogg JM. Ipilimumab Treatment Associated Pituitary Hypophysitis: Clinical Presentation and Imaging Diagnosis. Clin Neurol Neurosurg 2014 Oct;125:125-30. PMID: 25127260.

34. **Boxerman JL**, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence from Pseudoprogression in Patients with a High-Grade Glioma. Am J Clin Oncol, 2017 Jun;40(3):228-34 [Epub ahead of print in 2014]. PMID: 25436828.

35. Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, **Boxerman JL**. Dynamic Susceptibility Contrast MRI Measures of Relative Cerebral Blood Volume as a Prognostic Marker for Overall Survival in Recurrent Glioblastoma: Results from the ACRIN 6677/RTOG 0625 Multi-Center Trial. Neuro Oncol. 2015 Aug;17(8):1148-56. PMID: 25646027.

36. Ellingson BM, Kim E, Woodworth DC, Marques H, **Boxerman JL**, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP. Diffusion MRI Quality Control and Functional Diffusion Map (fDM) Results in ACRIN-6677/RTOG-0625: A Multicenter, Randomized, Phase II Trial of Bevacizumab and Chemotherapy in Recurrent Glioblastoma. Int J Oncol. 2015 May;46(5):1883-92. PMID: 25672376.

37. Welker K, **Boxerman JL**, Kalnin A, Kaufmann T, Shiroishi M, Wintermark M. MR Perfusion Standards and Practice Subcommittee of the ASFNR Clinical Practice Committee: Guidelines for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain. AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51. PMID: 25907520.

38. **Boxerman JL**, Ellingson BM. Response Assessment and MR Imaging Issues for Clinical Trials in High-Grade Gliomas. Top Magn Reson Imaging. 2015 Jun;24(3):127-36. PMID: 26049816.

39. Ellingson BM, Bendszus M, **Boxerman JL**, Barboriak DP, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Pope WB, Knopp MV, Cha S, van den Bent MJ, Chang S, Al Yung WK, Cloughesy TF, Wen PY, Gilbert MR. Consensus Recommendations for a Standardized Brain Tumor Imaging Protocol (BTIP) in Clinical Trials. Neuro Oncol. 2015 Sep;17(9):1188-98. PMID: 26250565.

40. Goldmacher GV, Ellingson BM, **Boxerman JL**, Barboriak D, Pope WB, Gilbert M. Standardized Brain Tumor Imaging Protocol for Clinical Trials. AJNR Am J Neuroradiol. 2015 Oct;36(10):E65-6. PMID: 26359146.

41. Shiroishi MS, **Boxerman JL**, Pope WB. Physiologic MRI for Assessment of Response to Therapy and Prognosis in Glioblastoma. Neuro Oncol. 2016 Apr;18(4):467-78. PMID: 26364321.

42. Elinzano H, Glantz M, Mrugala M, Kesari S, Kim L, Jeyapalan S, Pan E, Yunus S, Coyle T, Kinsella T, Evans D, Mantripragada K, **Boxerman JL**, Dipetrillo T, Donahue J, Hebda N, Mitchell K, Rosati K, Safran H. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation - A Randomized Phase II Study: BrUOG 244. Am J Clin Oncol. 2018 Feb;41(2):159-62 [Epub ahead of print in 2015]. PMID: 26658237.

43. Leu K, **Boxerman JL**, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Bidirectional Contrast Agent Leakage Correction of DSC-MRI Improves Cerebral Blood Volume Estimation and Survival Prediction in Recurrent Glioblastoma Treated with Bevacizumab. J Magn Reson Imaging. 2016 Nov;44(5):1229-1237. PMID: 26971534.

44. Leu K, **Boxerman JL**, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB, Ellingson BM. Improved Leakage Correction for Dynamic Susceptibility Contrast (DSC) Perfusion MRI Estimates of Relative Cerebral Blood Volume (rCBV) in Brain Tumors by Accounting for Interstitial Contrast Agent Washout Rate. AJNR Am J Neuroradiol. 2016 Aug;37(8):1440-6. PMID: 27079371.

45. Iyengar RJ, Klinge PM, Chen WS, **Boxerman JL**, Sullivan SR, Taylor HO. Management of Craniosynostosis at an Advanced Age: Controversies, Clinical Findings and Surgical Treatment. J Craniofac Surg. 2016 Jul;27(5):e435-41. PMID: 27380569.

46. **Boxerman JL**, Shiroishi MS, Ellingson BM, Pope WB. Dynamic Susceptibility Contrast MRI in Glioma: Review of Current Clinical Practice. Magn Reson Imaging Clin N Am. 2016 Nov;24(4):649-670. PMID: 27742108.

47. Dibble EH, **Boxerman JL**, Baird GL, Donahue J, Rogg JM. Toxoplasmosis versus Lymphoma: Cerebral Lesion Characterization Using DSC-MRI Revisited. Clin Neurol Neurosurg. 2017 Jan;152:84-89. PMID: 27940418.

48. Leu K, **Boxerman JL**, Ellingson BM. Effects of MRI Protocol Parameters, Preload Injection Dose, Fractionation Strategies, and Leakage Correction Algorithms on the Fidelity of Dynamic Susceptibility Contrast MRI Estimates of Relative Cerebral Blood Volume in Gliomas. AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484. PMID: 28034995.

49. Ellingson BM, Chung C, Pope WB, **Boxerman JL**, Kaufmann TJ. Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017 Sep;134(3):495-504. PMID: 28382534.

50. Semmineh NB, Stokes AM, Bell LC, **Boxerman JL**, Quarles CC. A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC) MRI Methods for Clinical Trials. Tomography. 2017 Mar;3(1):41-49. PMID: 28584878.

51. **Boxerman JL**, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Mohan S, Marques H, Sorensen AG, Gilbert MR, Barboriak DP. Prognostic Value of Contrast Enhancement and FLAIR for Survival in Newly Diagnosed Glioblastoma Treated With and Without Bevacizumab: Results from ACRIN 6686. Neuro Oncol. 2018 Sep;20(10):1400-10. PMID: 29590461.

52. Patel KM, Johnson J, Zacharioudakis IM, **Boxerman JL**, Flanigan TP, Reece RM. First Confirmed Case of Powassan Neuroinvasive Disease in Rhode Island. IDCases. 2018 Mar 23;12:84-87. PMID: 29942757.

53. Patel KM, Johnson J, **Boxerman JL**, Nau G. Two cases of group A streptococcus acute otitis media progressing to neuroinvasive disease in the elderly. IDCases. 2018 May 23;12:161-164. PMID: 29942780.

54. Adjepong K, **Boxerman JL**, Roth JL. Seeing Stars: Acute Repetitive Occipital Seizures in Hyperglycemia. Accepted to Neurographics, January 2018.

55. Semmineh NB, Bell LC, Stokes AM, Hu L, **Boxerman JL**, Quarles CC. Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast (DSC) MRI Using a Population-based Digital Reference Object. AJNR Am J Neuroradiol. 2018 Nov;39(11):1981-1988. PMID: 30309842.

56. Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry RC, Bokstein F, Sorensen AG, Gilbert MR, **Boxerman JL**. Inter-reader Variability in Dynamic Contrast-Enhanced Imaging of Patients with Recurrent Glioblastoma Multiforme: Results from the Multi-Center ACRIN 6677 / RTOG 0625 Study. Radiology. 2019 Feb;290(2):467-476. PMID: 30480488.

57. Moldovan K, **Boxerman JL**, O'Muircheartaigh J, Dean D, Eyerly-Webb S, Cosgrove GR, Pucci F, Deoni S, Spader H. Myelin Water Fraction Changes in Febrile Seizures. Clin Neurol Neurosurg. 2018 Dec;175:61-67. PMID: 30384118.

58. Bell LC, Semmineh N, An H, Eldeniz C, Wahl R, Schmainda KM, Prah MA, Erickson BJ, Korfiatis P, Sorace AG, Yankeelov TE, Rutledge N, Chenevert TL, Malyarenko D, Liu Y, Brenner A, Huang S, Hu LS, Zhou Y, **Boxerman JL**, Yen YF, Kalpathy-Cramer J, Beers AL, Muzi M, Madhuranthakam AJ, Pinho M, Johnson B, Quarles CC. Evaluating Multi-Site CBV Consistency from DSC-MRI Protocols and Post-Processing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO). Tomography. 2019 Mar;5(1):110-117. PMID: 30854448.

59. Schmainda KM, Prah MA, Semmineh N, Quarles CC, Hu L, Liu Y, Logan B, **Boxerman JL**. Moving Towards a Consensus DSC-MRI Protocol: A Low Flip Angle, Single-Dose Methodology as a Reference Standard for Brain Tumors. AJNR Am J Neuroradiol first published on 28 March 2019 doi:10.3174/ajnr.A6015.

60. Schmainda KM, Prah MA, Zhang Z, Snyder BS, Bedekar D, Rand S, Barboriak DP, **Boxerman JL**. Delta T1 Technology Outperforms Central Reader Analysis for the Determination of Contrast-agent Enhancing Brain Tumor ROIs: Retrospective Sub-Analysis of ACRIN 6677 / RTOG 0625 Multi-Center Data. Accepted to AJNR Am J Neuroradiol, May 2019.

61. Chang K, Beers AL, Bai HX, Brown J, Ly KI, Li X, Senders JT, Kavouridis VK, Boaro A, Su C, Bi WL, Rapalino O, Liao W, Shen Q, Zhou H, Xiao B, Wang Y, Zhang PJ, Pinho MC, Wen PY, Batchelor TT, **Boxerman JL**, Arnaout O, Rosen BR, Gerstner ER, Yang L, Huang RY, Kalpathy-Cramer J. Automatic Assessment of Glioma Burden: A Deep Learning Algorithm for Fully Automated Volumetric and Bi-dimensional Measurement. Accepted to Neuro-oncology, June 2019.

62. Lee M, Baird G, Bell L, Quarles CC, **Boxerman JL**. Utility of Percent Signal Recovery and Average Baseline Signal in DSC-MRI Optimized for rCBV Measurement for Differentiation of GBM, Metastasis, Lymphoma and Meningioma. Accepted to AJNR Am J Neuroradiol pending revisions, June 2019.

OTHER PEER REVIEWED PUBLICATIONS

1. **Boxerman JL**, Schmainda KM, Zhang Z, Barboriak DP. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. Neuro Oncol. 2015 Nov;17(11):1538-9. PMID: 26361983.

NON-PEER REVIEWED PUBLICATIONS

GRADUATE THESES

1. **Boxerman JL**. Variable Block-Sized Vector Quantization of Grayscale Images with Unconstrained Tiling. S. M. Dissertation. Massachusetts Institute of Technology, June 1989. Advisor: Bruce Musicus, Ph.D.

Describes the design and performance evaluation of an image compression scheme using unconstrained image segmentation into multi-sized, non-overlapping rectangular regions, each of which is vector quantized. This scheme performs better in a rate-distortion sense than traditional variable block-sized vector quantizers for certain applications, including efficient compression in single-encode, multiple-decode applications such as medical image databases and servers.

2. **Boxerman JL**. Non-Invasive Measurement of Physiology Using Dynamic Susceptibility Contrast NMR Imaging. Ph.D. Dissertation, Massachusetts Institute of Technology, February 1995. Advisor: Robert Weisskoff, Ph.D. Committee Chair: David Cory, Ph.D. Readers: Bruce Rosen, M.D., Ph.D.; Deborah Burstein, Ph.D.; Alan Grodzinsky, Ph.D.

   Quantifies contrast due to magnetic susceptibility in functional magnetic resonance imaging. Computer models are applied to dynamic functional MRI studies aimed at quantifying cerebral blood volume and the hemodynamic changes associated with cortical neuronal activation using exogenous and endogenous contrast agents, respectively. This thesis provides both an improved understanding of the fundamental principles of susceptibility contrast, and a better ability to interpret physiologic images in this new generation of susceptibility-based functional MRI.

BOOK CHAPTERS

1. **Boxerman JL**, Weisskoff RM, Rosen BR. Susceptibility effects in whole body experiments. In: Grant DM, Harris KK, eds. Encyclopedia of Nuclear Magnetic Resonance. Chichester, UK: John Wiley and Sons, 1996; 4672-4679.

2. Bluemke DA, **Boxerman JL**. Acquired heart disease. In: Stark DD, Bradley WG, eds. Magnetic Resonance Imaging. St. Louis, MO: Mosby, 1999; 409-437.

3. **Boxerman JL**, Weisskoff RM, Rosen BR. Susceptibility effects in whole body experiments. In: Young IR, ed. Magnetic Resonance Imaging and Spectroscopy in Medicine and Biology. Chichester, UK: John Wiley and Sons, 2000.

4. Jayaraman MV, **Boxerman JL.** Adult Brain Tumors. In: Atlas SW, ed. Magnetic Resonance Imaging of the Brain and Spine, Fourth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2009; 445-590.

5. **Boxerman JL**, van Osch MJP, Schmainda KM. Susceptibility Contrast in Tissues: Gradient-Echoes vs. Spin-Echoes. Invited chapter in: Bammer R, ed. MR & CT Perfusion Imaging: Clinical Applications and Theoretical Principles. Philadelphia, PA: Lippincott Williams & Wilkins, 2016; Chapter 11.

6. Schmainda KM, Paulson ES, **Boxerman JL**. The Effects of Contrast Agent Extravasation on rCBV Derived from Dynamic Susceptibility Contrast MRI. Invited chapter in: Bammer R, ed. MR & CT Perfusion Imaging: Clinical Applications and Theoretical Principles. Philadelphia, PA: Lippincott Williams & Wilkins, 2016; Chapter 28.

7. Telles B, D'Amore F, **Boxerman JL**, Jayaraman MV, Law M, Shiroishi MS, Lerner A. Adult Brain Tumors. In: Atlas SW, ed. Magnetic Resonance Imaging of the Brain and Spine, Fifth Edition. Philadelphia, PA: Wolters Kluwer Health, 2016; Chapter 8.

8. Kickingereder P, Park JE, **Boxerman JL**. Advanced Physiologic Imaging: Perfusion. Theory and Applications. In: Pope W, ed. Glioma Imaging: Physiologic, Metabolic, and Molecular Approaches. To be published by Springer International Publishing AG, 2019; Chapter 2.

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

1. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):322-33. PMID: 24450891. **(Site investigator.)**

PAPERS SUBMITTED, AWAITING DECISION

1. Boyd C, Jayaraman MV, Baird GL, Einhorn WS, Stib MT, Atalay MK, **Boxerman JL**, Lourenco AP, Jindal G, Hidlay DT, Dibiasio EL, McTaggart RA. Impact of Experience and Grayscale Inversion on the Detection of Emergent Large Vessel Occlusion Stroke with CT Angiography. Submitted to European Radiology, February 2019.

PAPERS NEAR SUBMISSION OR IN PREPARATION

1. **Boxerman JL**, Zhang Z, Schmainda KM, Snyder BS, Prah M, Sorensen AG, Gilbert MR, Barboriak DP. Early Post-Bevacizumab Change in rCBV from DSC-MRI Predicts Overall Survival in Recurrent Glioblastoma Whereas Conventional 2D-T1 Response Status Does Not: Results from ACRIN 6677/RTOG 0625. To be submitted to AJNR Am J Neuroradiol.

2. **Boxerman JL**, Schmainda KM, Zhang Z, Snyder BS, Barboriak DP. Treatment of newly diagnosed GBM with bevacizumab results in early decreases in rCBV with improvements in PFS but not OS: Results from ACRIN 6686/RTOG 0825. To be submitted to J Neuro-oncol.

3. **Boxerman JL**, Quarles CC, Ellingson BM, Schmainda KM, and the Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Glioma Clinical Trials. To be submitted to Neuro-oncology.

MEETING PRESENTATIONS AND PUBLISHED ABSTRACTS

1. **Boxerman JL**, Lee HJ. Variable block-sized vector quantization of grayscale images with unconstrained tiling. **Platform presentation** at ICASSP '90, IEEE Acoustics, Speech, and Signal Processing Society, Albuquerque, NM, 1990; 2177-2180.

2. **Boxerman JL**, Lee HJ. Variable block-sized vector quantization of grayscale images with unconstrained tiling. SPIE's Visual Communications and Image Processing, International Society of Optical Engineering (USA). Lausanne, Switzerland, 1990.

3. Aronen HJ, **Boxerman JL**, Goldberg IE, et al. Susceptibility-contrast CBV imaging: optimization of contrast dose and imaging sequences. Eleventh Meeting of the Society of Magnetic Resonance in Medicine. Berlin, 1992; 1129.

4. Zuo CS, **Boxerman JL**, Weisskoff RM. Compartment size determines T2 relaxivity in susceptibility contrast agents: Theory and experiment. Eleventh Meeting of the Society of Magnetic Resonance in Medicine. Berlin, 1992; 866.

5. **Boxerman JL**, Weisskoff RM, Aronen HJ, Rosen BR. Signal-to-noise and tissue blood volume maps from dynamic NMR imaging studies. **Platform presentation** at Eleventh Meeting of the Society of Magnetic Resonance in Medicine. Berlin, 1992; 1130.

6. Weisskoff RM, Chesler D, **Boxerman JL**, Rosen BR. Measurement of hemodynamics with intravascular tracers and MR imaging. Functional MRI of the Brain. SMRM Workshop. Arlington, VA, 1993; 75-82.

7. Weisskoff RM, **Boxerman JL**, Zuo CS, Rosen BR. Endogenous susceptibility contrast: Principles of relationship between blood oxygenation and MR signal change. Functional MRI of the Brain. SMRM Workshop. Arlington, VA, 1993; 103-110.

8. **Boxerman JL**, Weisskoff RM, Hoppel BE, Hamberg LM, Rosen BR. MR contrast due to microscopically heterogeneous magnetic susceptibility: Cylindrical geometry. **Platform presentation** at Twelfth Meeting of the Society of Magnetic Resonance in Medicine. New York, 1993; 389.

9. Weisskoff RM, **Boxerman JL**, Sorensen AG, Kulke SM, Campbell TA, Rosen BR. Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. Second Annual Meeting of the Society of Magnetic Resonance. San Francisco, 1994; 279.

10. **Boxerman JL**, Weisskoff RM, Rosen BR. The effects of water permeability, red blood cell velocity and agent compartmentalization on susceptibility contrast relaxivity. **Platform presentation** at Second Annual Meeting of the Society of Magnetic Resonance. San Francisco, 1994; 1008.

11. **Boxerman JL**, Weisskoff RM, Kwong KK, Davis TL, Rosen BR. The intravascular contribution to fMRI signal change: Modeling and diffusion-weighted *in vivo* studies. **Platform presentation** at Second Annual Meeting of the Society of Magnetic Resonance. San Francisco, 1994; 619.

12. Østergaard L, Weisskoff RM, Chesler DA, Kwong KK, Sorensen AG, Davis TL, **Boxerman JL**, Gyldensted C, Rosen BR. High resolution measurement of cerebral plasma flow, mean transit time and volume using dynamic imaging of Gd-DTPA bolus passages. Third Annual Meeting of the Society of Magnetic Resonance. Nice, France, 1995; 875.

13. Bandettini PA, **Boxerman JL**, Davis TL, Wong EC, Weisskoff RM, Rosen BR. Numerical simulations of the oxygenation dependence of the T2 and $T2^*$ of whole blood using a deterministic diffusion model. Third Annual Meeting of the Society of Magnetic Resonance. Nice, France, 1995; 456.

14. Sorensen AG, Gonzalez RG, Weisskoff RM, Davis TL, Reese TG, Copen WA, **Boxerman JL**, Sasson JP, Rosen BR. *In vivo* full diffusion tensor measurement in normal and pathologic human brain. Fourth Annual Meeting of the Society of Maganetic Resonance. New York, 1996; 1327.

15. Weisskoff RM, **Boxerman JL**. Susceptibility contrast: does order matter? Fourth Annual Meeting of the Society of Magnetic Resonance. New York, 1996; 471.

16. Bluemke DA, **Boxerman JL**, Kawamoto S. Dynamic contrast-enhanced MR with fat suppression: effect of tissue composition on perfusion parameters. 5th Annual Meeting of the Society of Magnetic Resonance. Vancouver, BC, 1997; 1615.

17. **Boxerman JL**, Reeder SB, Zerhouni EA. Standard vs. centric segmented k-space phase encoding: SNR comparison in breath-hold SPGR cardiac imaging. **Platform presentation** at 5th Annual Meeting of the Society of Magnetic Resonance. Vancounver, BC, 1997; 138.

18. Bluemke DA, **Boxerman JL**, Intravenous vascular access planning: Evaluation of the entire body using MR venography. 6th Annual Meeting of the Society of Magnetic Resonance. Sydney, Australia, 1998; 843.

19. Herzka DA, **Boxerman JL**, Post WS, Reeder SB, Faranesh AZ, Chin BB, Hill MN, Shapiro EP, Weiss JL, McVeigh ER, Beache GM. Heterogeneity of BOLD-indexed myocardial perfusion reserve. 7th Annual Meeting of the Society of Magnetic Resonance. Philadelphia, PA, 1999; 1277.

20. **Boxerman JL**, Rand SD, Krouwer HGJ, Schmainda KM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade whereas uncorrected maps do not. **Platform presentation** at American Society of Neuroradiology 42nd Annual Meeting. Seattle, WA, 2004.

21. Goldman M, **Boxerman JL**, Rogg J, Noren G. The utility of apparent diffusion coefficient for predicting response of non-small cell lung cancer brain metastases to stereotactic radiosurgery. American Society of Neuroradiology 44th Annual Meeting. San Diego, CA, 2006.

22. **Boxerman JL**, Rogg J, Donahue JE, Goldman M, Duncan J. Evaluation of MRI criteria for predicting surgical success of transsphenoidal pituitary macroadenoma resection: tumor ADC relates significantly with inadequate resection. **Platform presentation** at American Society of Neuroradiology 44th Annual Meeting, San Diego, CA, 2006.

23. **Boxerman JL**, Hawash K, Bali B, Clarke T, Rogg J, and Pal DK. No Excess of neuroimaging abnormalities associated with rolandic epilepsy. 10th International Child Neurology Congress, Montreal, 2006.

24. Goldman M, **Boxerman JL**, Rogg J, Park M, and Noren G. The utility of apparent diffusion coefficient for predicting response of brain metastases to gamma knife radiosurgery. 13th International Meeting of the Leksell Gamma Knife Society, Seoul, Korea, May 21-25, 2006.

25. Goldman M, **Boxerman JL**, Rogg J, Park M, and Noren G. Initial tumor volume decrease is not predictive of therapeutic response to gamma knife radiosurgery for intracranial breast and non-small cell lung metastases 13th International Meeting of the Leksell Gamma Knife Society, Seoul, Korea, May 21-25, 2006.

26. **Boxerman JL,** Prah DE, Paulson ES, and Schmainda KM. The Role of Pre-dose and Leakage Correction in Gd-based Cerebral Blood Volume Estimation Determined by Comparison to MION as a Gold Standard. **Platform presentation** at American Society of Neuroradiology 45th Annual Meeting, Chicago, IL, 2007.

27. Walsh EG, **Boxerman JL**, Xie J, Nu C, Kohler N, Sun S. MRI Observations of Static Dephasing with Cellular Uptake of PEG-Coated Iron Oxide Nanoparticles. Joint Molecular Imaging 2007 Conference, Providence, RI, September 2007, Program Number 345.

28. **Boxerman JL**, Rogg JM, Donahue JE, Machan JT, Goldman MA, and Doberstein CE. Pre-operative MR Evaluation of Pituitary Macroadenomas: Imaging Features that Predict Successful Transsphenoidal Surgery. **Platform presentation** at American Roentgen Ray Society 110th Annual Meeting, San Diego, CA, 2010, Presentation 204.

29. DiPetrillo TA, O'Connor BM, Jeyapalan S, **Boxerman JL**, Goldman M, Kahn J, Blitstein M, Cielo D, Oyelese A, Doberstein C. Addition Of Paclitaxel Poliglumex (PPX) To IMRT Plus Concurrent Temozolomide In The Treatment Of High-Grade Gliomas. American Society of Radiation Oncology 52nd Annual Meeting, San Diego, CA, 2010, Presentation 2128.

30. Jeyapalan S, Goldman M, **Boxerman JL**, Donahue J, Elinzano H, Evans D, ‡O'Connor B, Puthawala MY, Oyelese A, Cielo D, Blitstein M, Dargush M, Santaniello A, Constantinou M, Dipetrillo T, and Safran H. Paclitaxel Poliglumex (PPX), Temodar (TMZ) and Radiation (RT) for Newly Diagnosed High-Grade Gliomas: A Brown University Oncology Group Phase II Study. American Society of Neuro-oncology 15th Annual Meeting, Montreal, Quebec, 2010, Presentation OT-20.

31. Sorensen AG, Zhang Z, **Boxerman JL**, Safriel Y, Gimpel J, Snyder B, Girardi V, Larvie M, Gilbert M. Increased Progression with T2-based Imaging during Anti-VEGF Therapy in Glioblastoma: ACRIN 6677 / RTOG 0625. RSNA 96th Scientific Assembly, 2010, Presentation SSA15-07.

32. Mehan W, **Boxerman JL,** Rogg J, Haas R, Jayaraman M. What Is the Added Value of CTP above CTA in Decision Making for Intra-Arterial Stroke Therapy? RSNA 96th Scientific Assembly, 2010, Presentation SSC12-05.

33. Blitstein MK, **Boxerman JL**, Rogg J, Elinzano H, Jeyapalan S, Goldman M, Dargush M, Santaniello A, Dipetrillo T, Safran H. The Role of Longitudinal Perfusion-Weighted MRI Measures in Distinguishing Tumor Recurrence from Pseudoprogression in a Cohort of Patients with High-Grade Gliomas Receiving Radiation Therapy (IMRT), Temozolomide (TMZ) and Paclitaxel Poliglumex (PPX). American Society of Neuroradiology 49th Annual Meeting, Seattle, June 2011, Presentation 539.

34. Blitstein MK, Rogg JM, **Boxerman JL**, Klinge P, Sampath P Mandelbaum D. Clinical correlation and significance of MRI findings in Chiari I malformation. American Society of Neuroradiology 49th Annual Meeting, Seattle, June 2011, Presentation 485.

35. Jeyapalan S, Goldman M, **Boxerman JL**, Donahue J, Elinzano H, Evans D, ‡O'Connor B, Puthawala MY, Oyelese A, Cielo D, Blitstein M, Dargush M, Santaniello A, Constantinou M, Dipetrillo T, and Safran H. A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas. American Society of Clinical Oncology 2011 Annual Meeting, Chicago, June 2011, presentation 2036 (poster discussion session).

36. Donahue J, Jeyapalan S, Goldman M, Elinzano H, **Boxerman JL**, Dipetrillo T, Safran H. Pathology of 'Pseudoprogression' in a Phase II Study of PPX, TMZ, and RT for Newly Diagnosed High-Grade Gliomas. American Association of Neuropathologists 87th Annual Meeting, Seattle, June 2011, presentation 52.

37. Ellingson BM, **Boxerman JL**, Jeyapalan S, Elinzano HD, Goldman M, Dipetrillo T, Safran H, Pope WB. Functional perfusion maps (fPMs) derived from serial DSC-MRI estimates of rCBV can differentiate pseudoprogression & quiescent tumor from progressive disease in malignant glioma patients treated with paclitaxel poliglumex (PPX). American Society of Neuroradiology 50th Annual Meeting, New York, April 2012, electronic poster 82.

38. Ellingson BM, **Boxerman JL**, Jeyapalan S, Elinzano HD, Goldman M, Dipetrillo T, Safran H, Pope WB. Time-dependent cell invasion, motility, and proliferation level estimate (CIMPLE map) characteristics of malignant gliomas treated with paclitaxel poliglumex (PPX). American Society of Neuroradiology 50th Annual Meeting, New York, April 2012, electronic poster 75.

39. Jayaraman MV, **Boxerman JL**, Rogg JM, Silver B. Can patient selection for IA stroke therapy be optimized without "Advanced Imaging"? American Society of Neuroradiology 50th Annual Meeting, New York, April 2012, electronic poster 158.

40. Ratai EM, Zheng Z, Snyder B, Yeh M, Gilbert M, L'Heureux DZ, **Boxerman JL**, Sorensen AG, Barboriak D. MR spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: ACRIN 6677 / RTOG 0625. International Society of Magnetic Resonance in Medicine 20th Annual Meeting, Melbourne, Australia, May 2012, electronic poster.

41. Semmineh NB, **Boxerman JL**, Xu J, Quarles CC. Cell Density and Spacing Influence DSC-MRI Data Acquired in Brain Tumors. International Society of Magnetic Resonance in Medicine 20th Annual Meeting, Melbourne, Australia, May 2012, electronic poster (#4248).

42. Semmineh NB, **Boxerman JL**, Xu J, Delaney GW, Gore JC, Quarles CC. Cell Geometry, Density and Spatial Distribution Influence DSC-MRI Data Acquired in Brain Tumors. International Society of Magnetic Resonance in Medicine Workshop on Perfusion MRI, Amsterdam, Netherlands, October 2012, poster presentation (poster #9).

43. **Boxerman JL**, Zheng Z, Safriel Y, Larvie M, Gimpel J, Snyder B, Yeh M, Sorensen AG, Barboriak D, Gilbert M. Early Post-Bevacizumab Progression Status by MRI Predicts Overall Survival in Recurrent Glioblastoma: Results from the ACRIN 6677/RTOG 0625 Central Reader Study. **Platform presentation** at RSNA 98th Scientific Assembly, 2012, Presentation VSNR21-05.

44. Spader HS, Deoni SC, Dean D, Muircheartaigh J, **Boxerman JL**, Cosgrove GR. Using a Novel Myelin Imaging Technique to Identify Previously Occult Seizure Foci. American Association of Neurological Surgeons 81st Annual Scientific Meeting, New Orleans, April 2013, Presentation 640.

45. Farnam J, **Boxerman JL**, Jeyapalan S, Elinzano H, Goldman M, Safran H. Extreme Pseudoprogression on MRI of High-grade Gliomas Treated with Paclitaxel Poliglumex: Comparison with Conventional Pseudoprogression and True Tumor Progression. American Society of Neuroradiology 51st Annual Meeting, San Diego, May 2013, presentation as an education exhibit (EdE-16).

46. Semmineh NB, Xu J, **Boxerman JL**, Delaney GW, Quarles CC. DSC-MRI Derived T2* Leakage Effect Depends on Structural Features of Extravascular Space. International Society of Magnetic Resonance in Medicine 21st Annual Meeting, Salt Lake City, May 2013, accepted as a poster presentation (poster #4809).

47. Elinzano H, Kadivar F, Yadav PO, Breese VL, Jackson CL, Donahue JE, **Boxerman JL**. Analysis of Perfusion and Volumetric MRI in Progressive Glioblastoma Patients Treated with Continuous Dose Intense Temozolomide. Society for Neuro-oncology 18th Annual Meeting, San Francisco, November 2013, accepted as a poster presentation.

48. Schmainda KM, Zhang Z, **Boxerman JL**, Prah M, Snyder B, Bedekar D, Sorensen AG, Gilbert MR, Barboriak DP. DSC-MRI Measures of Relative Cerebral Blood Volume (rCBV) as a Prognostic Marker for Progression-Free and Overall Survival in Recurrent Glioblastoma: Results from the ACRIN 6677/RTOG 0625 Multi-Center Trial. International Society of Magnetic Resonance in Medicine 22nd Annual Meeting, Milan, Italy, May 2014, oral platform presentation (#0280).

49. Iyengar RJ, Klinge PM, **Boxerman JL**, Sullivan SR, Taylor HO. Management of Craniosynostosis at An Advanced Age: Clinical Findings, Surgical Treatment, and Controversies. New England Society of Plastic and Reconstructive Surgeons 55th Annual Meeting, Sebasco Harbor, ME, June 2014, oral platform presentation.

50. Barboriak DP, Zhang Z, Snyder B, Safriel Y, McKinstry RC, Bokstein F, Sorensen AG, Gilbert MR, **Boxerman JL**. Inter-reader variability in dynamic contrast-enhanced MR imaging (DCE-MRI) of patients with recurrent glioblastoma multiforme: results from the multi-center ACRIN 6677 / RTOG 0625 study. RSNA 100th Scientific Assembly, Chicago, 2014, Poster presentation NRS455.

51. **Boxerman JL**, Zhang Z, Schmainda KM, Snyder BS, Prah M, Safriel Y, Sorensen AG, Gilbert MR, Barboriak DP. Early Post-Bevacizumab Change in rCBV from DSC-MRI Predicts Overall Survival in Recurrent Glioblastoma Whereas 2D-T1 Response Status Does Not: Results from the ACRIN 6677/RTOG 0625 Multi-Center Study. **Platform presentation** at RSNA 100th Scientific Assembly, Chicago, 2014, presentation VSNR51-10.

52. Iyengar RJ, Klinge PM, **Boxerman JL**, Sullivan SR, Taylor HO. Management of craniosynostosis at an advanced age. Presented by Iyengar RJ. Rhode Island Hospital Research Day, Providence, Rhode Island, October 2, 2014.

53. Klinge PM, Taylor HO, **Boxerman JL**, Sullivan SR. Multidisciplinary management of craniosynostosis in school kids and adolescents. Congress of Neurological Surgeons 2014

Annual Meeting, Boston, October 18-22, 2014, Poster presentation.

54. Iyengar RJ, Klinge PM, **Boxerman JL**, Sullivan SR, Taylor HO. Management of craniosynostosis at an advanced age: Clinical findings, surgical treatment, and controversies. Poster presentation at 72nd Annual Meeting of the American Cleft Palate-Craniofacial Association, Palm Springs, CA, April 20-25, 2015.

55. Dibble EH, Rogg JM, Donahue J, **Boxerman JL**. Toxoplasmosis versus Lymphoma: Cerebral Lesion Characterization Using Dynamic Susceptibility Contrast MRI and Relative Cerebral Blood Volume Estimates. American Society of Neuroradiology 53rd Annual Meeting, Chicago, April 2015, oral presentation O-173.

56. Ellingson BM, Kim E, Woodworth DC, Marques H, **Boxerman JL**, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP. Diffusion MRI Quality Control and Functional Diffusion Map (fDM) Results in ACRIN 6677/RTOG 0625: A multicenter, Randomized, Phase II Trial of Bevacizumab and Chemotherapy in Recurrent Glioblastoma. American Society of Neuroradiology 53rd Annual Meeting, Chicago, April 2015, oral presentation O-70.

57. Klinge PM, Iyengar R, Sullivan SR, Chen W, **Boxerman JL**, Taylor HO. Controversies in the Management of Craniosynostosis at an Advanced Age. 7th Annual Meeting of the International Society of Hydrocephalus and CSF disorders, Banff, September 2015, oral presentation.

58. Dibble EH, Swenson DW, Cobb C, **Boxerman JL**, Movson JH. The RADCAT 3 System for Closing the Loop on Important Non-Urgent Radiology Findings: A User-Friendly Multidisciplinary System-Wide Approach. Accepted for presentation at the American Society for Emergency Radiology's 2015 Annual Scientific Meeting and Postgraduate Course Conference, Key Biscayne, FL, September 2015, oral presentation.

59. Leu K, **Boxerman JL**, Cloughesy TF, Lai A, Nghiemphu PL, Liau L, Pope WB, Ellingson BM. Improved Leakage Correction for Dynamic Susceptibility Contrast (DSC) Perfusion MRI Estimates of Relative Cerebral Blood Volume (rCBV) in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. 20th Annual Meeting of the Society for Neuro-Oncology, San Antonio, November 2015, oral presentation.

60. Punsoni M, Julian J, Jolly G, **Boxerman JL**, Choi DB, Chopra P, Donahue JE, Moldovan K, Stopa EG, Klinge PM. Filum Pathology of Occult Tethered Cord Syndrome in Ehlers Danlos Patients. 2016 Annual Meeting of the United States and Canadian Academy of Pathology, Seattle, WA, March 2016, poster presentation.

61. Semmineh NB, Gardner K, **Boxerman JL**, Quarles CC. The Influence of Pre-load Contrast Agent Dosing Schemes on DSC-MRI Data. 24th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Singapore, May 2016, poster presentation (6171).

62. **Boxerman JL**, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Marques H, Gimpel J, Sorensen

AG, Gilbert MR, Barboriak DP. Assessment of the Prognostic Value of Contrast Enhancement and FLAIR for Overall Survival in Newly Diagnosed Glioblastoma Treated With and Without Bevacizumab: Results from the ACRIN 6686/RTOG 0825 Central Reader Study. **Platform presentation** at RSNA 102nd Scientific Assembly, Chicago, 2016, presentation RC305-08.

63. Leu K, **Boxerman JL**, Ellingson BM. Optimized Image Acquisition and Leakage Correction Post-Processing of Dynamic Susceptibility Contrast (DSC) MRI for Highest Accuracy of Relative Cerebral Blood Volume (rCBV) Quantification in Human Brain Tumors. **Platform presentation** at RSNA 102nd Scientific Assembly, Chicago, 2016, presentation SST08-05.

64. Dibble EH, Furman MS, Lourenco AP, Swenson DW, **Boxerman JL**, Cassese JA. What can go wrong: Pediatric neuroaxis abnormalities from fetal life to neonatal life. Accepted for presentation at the American Roentgen Ray Society 2017 Annual Scientific Meeting, New Orleans, LA, April 30-May 5 2017, electronic exhibit.

65. Semmineh NB, Stokes AM, Bell LC, **Boxerman JL**, Quarles CC. Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast (DSC) MRI Using a Validated Digital Reference Object. Accepted for presentation at the 25th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Honolulu, HI, April 2017, oral presentation.

66. Semmineh NB, Stokes AM, Bell LC, **Boxerman JL**, Quarles CC. A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC) MRI Methods for Clinical Trials. Accepted for presentation at the 25th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Honolulu, HI, April 2017, poster presentation.

67. **Boxerman JL**, Quarles CC, Prah M, Schmainda KM. A Comparison of Low Flip-Angle, No- Preload DSC-MRI to Intermediate Flip- Angle, Preload-Based DSC-MRI as a Reference Standard. **Platform presentation** at ASNR American Society of Neuroradiology 56th Annual Meeting, Vancouver, BC, June 4, 2018, presentation O-33.

68. Lee M, Baird G, Bell L, Quarles CC, **Boxerman JL**. Utility of Percent Signal Recovery and Average Baseline Signal in DSC-MRI Optimized for rCBV Measurement for Differentiation of GBM, Metastasis, Lymphoma and Meningioma. Platform presentation at ASNR American Society of Neuroradiology 56th Annual Meeting, Vancouver, BC, June 4, 2018, presentation O-35.

69. Baker A, **Boxerman JL**, Klinge P, Baird G, Rogg JM. Radiographically Occult Tethered Cord in Pediatric and Adult Patients. Platform presentation at ASNR American Society of Neuroradiology 56th Annual Meeting, Vancouver, BC, June 5, 2018, presentation O-208.

70. Kim YR, **Boxerman JL**. Evaluation of Transvascular Water Exchange Index (WEI) in Post-thrombectomy Patients. Multimedia Electronic Poster presentation at 26th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Paris, France,

June 2018.

71. Stib MT, Dong MP, Kim YH, Subzwari SS, Triedman HJ, Wang A, Yao AD, Zhu LL, **Boxerman JL**, Baird G, Cetintemel U, Eickhoff C, McTaggart RA. Deep Learning in Emergent Large Vessel Occlusion Detection using Maximum Intensity Projections via CT Angiography. Poster presentation at SIIM Machine Learning Conference, San Francisco, September 2018.

72. Lotter B, **Boxerman JL**, Sorensen AG. Improved Performance of Machine Learning-Based Analysis of Mammography by Using Digital Breast Tomosynthesis Versus 2D Mammography. Scientific presentation at RSNA 104th Scientific Assembly, Chicago, November 2018.

73. Yao AD, Stib MT, Dong MP, Kim YH, Subzwari SS, Triedman HJ, Wang A, Zhu LL, **Boxerman JL**, Baird G, Cetintemel U, Eickhoff C, McTaggart RA. Utilization of Deep Learning on CT Angiogram to Aid in the Diagnosis of Emergent Large Vessel Occlusion (ELVO). Poster presentation at RSNA 104th Scientific Assembly, Chicago, November 2018.

74. Dong MP, Kim YH, Subzwari SS, Triedman HJ, Wang A, Zhu LL, Yao AD, Baird G, Cetintemel U, Eickhoff C, Stib MT, **Boxerman JL**, McTaggart RA. Machine Learning for ELVO Detection. Technical abstract presentation, MIT Undergraduate Machine Intelligence Conference, Cambridge, MA, November 2018.

75. Hays S, DiBiasio E, Caine A, Baird G, Cutting S, Yaghi S, **Boxerman JL**, Jindal G, Burton T, Saad A, Mac Grory B, Furie K, McTaggart R, Jayaraman M. CT and Multiphase CTA alone can identify thrombectomy candidates beyond 6 hours. Poster presentation at International Stroke Conference 2019, Honolulu, HI.

76. Stib MT, Dong MP, Kim YH, Subzwari SS, Triedman HJ, Wang A, Yao AD, Zhu LL, **Boxerman JL**, Baird G, Cetintemel U, Eickhoff C, McTaggart RA. Localizing Large Vessel Occlusions on CT Angiography Using a 3-D Deep Learning Model. Poster presentation at International Stroke Conference 2019, Honolulu, HI.

77. Prah MA, Hu L, **Boxerman JL**, Quarles CC, Connelly JM, Schmainda KM. Evaluation of Fractional Tumor Burden (FTB) fidelity using a no-preload, low-flip angle dynamic susceptibility contrast MRI acquisition scheme. Accepted for presentation at the 27th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Montreal, Quebec, May 2019, oral presentation.

78. Semmineh NB, Bell LC, Stokes AM, Mathew E, Lee MD, **Boxerman JL**, Quarles CC. Investigating the Influence of DSC-MRI Acquisition Methods on the Clinical Application of Percentage Signal Recovery in Brain Tumors. Accepted for presentation at the 27th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Montreal, Quebec, May 2019, oral presentation.

79. Bell LC, Semmineh N, An H, Eldeniz C, Wahl R, Schmainda KM, Prah MA, Erickson BJ,

Korfiatis P, Wu C, Sorace AG, Rutledge N, Yankeelov TE, Chenevert TL, Malyarenko D, Liu Y, Brenner A, Hu LS, Zhou Y, **Boxerman JL**, Yen YF, Kalpathy-Cramer J, Beers AL, Muzi M, Madhuranthakam AJ, Pinho M, Johnson B, Quarles CC. Evaluating multi-site rCBV consistency from DSC-MRI imaging protocols and post- processing software across the NCI Quantitative Imaging Network sites using a Digital Reference Object. Accepted for presentation at the 27th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Montreal, Quebec, May 2019, oral presentation.

80. Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand S, Jensen T, Barboriak DP, **Boxerman JL**. Quantitative deltaT1 (qDT1) as a Replacement for Adjudicated Central ReaderAnalysis: A Sub-Analysis of the RTOG 0625/ACRIN 6677 Multi-Center Brain Tumor Trial. Accepted for presentation at the 27th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Montreal, Quebec, May 2019, oral presentation.

INVITED PRESENTATIONS

REGIONAL

1. *Overview of Cerebral CT Perfusion Imaging*. **Invited presentation**, Imaging Conference for Department of Diagnostic Imaging, Rhode Island Hospital, November 26, 2003.

2. *Overview of Cerebral MR Perfusion Imaging*. **Invited presentation**, Imaging Conference for Department of Diagnostic Imaging, Rhode Island Hospital, October 20, 2004.

3. *Cerebral MR Perfusion Imaging with Brain Tumor Applications*. **Invited presentation**, Neurosurgery Grand Rounds, Rhode Island Hospital, February 14, 2005.

4. *Overview of CT Perfusion Imaging of Acute Stroke*. **Invited presentation**, New England Roentgen Ray Society, Cambridge, MA, September 23, 2005.

5. *Overview of Radiology Case Conference Presentation*. **Invited presentation**, Imaging Conference for Department of Diagnostic Imaging, Rhode Island Hospital, December 14, 2005.

6. *Overview of Cerebral MR Perfusion Imaging with an Emphasis on Brain Tumor Applications*. **Invited presentation**, In-Service Training for MRI Technologists, Rhode Island Hospital, March 26, 2007.

7. *CT Perfusion Imaging of Acute Stroke at Rhode Island Hospital: a Primer*. **Invited presentation**, Imaging Conference for Department of Diagnostic Imaging, Rhode Island Hospital, December 4, 2007.

8. *fMRI and Pre-operative Planning for Brain Tumors at RIH: An Update*. **Invited presentation**, Imaging Conference for Department of Diagnostic Imaging, Rhode Island Hospital, March 21, 2011.

9. *Panel of Unknown Cases, Neuroradiology*. **Invited faculty**, New England Roentgen Ray Society, Boston, MA, April 8, 2011.

10. *Some Practical Technical and Clinical Considerations about Quantitative DSC-MRI of Brain Tumors*. **Invited presentation** to the MGH Quantitative Tumor Imaging Group meeting, Massachusetts General Hospital, Charlestown, MA, July 12, 2013.

11. *Review of Imaging Results for ACRIN 6677 / RTOG 0625: Treatment of Recurrent GBM with Bevacizumabplus Irinotecan or Temozolomide.* **Invited presentation** to the Dana Farber/Brigham and Women's Hospital Neuro-Oncology Multidisciplinary Conference, Brigham and Women's Hospital, Boston, MA, March 6, 2015.

12. *Update on DSC Perfusion MRI in the Brain: Neuro-oncology Applications at Rhode Island Hospital*. **Invited presentation**, Imaging Conference for Department of Diagnostic Imaging, Rhode Island Hospital, October 7, 2015.

NATIONAL

1. *Mechanisms of signal change in functional magnetic resonance imaging*. **Invited presentation**, Annual Scientific Meeting of the Biomedical Engineering Society, Tempe, AZ, September 1994.

2. *Brain Tumor Imaging: T2 MRI Perfusion*. **Invited faculty**, ACRIN 2004 Fall meeting, Arlington, VA, October 8, 2004.

3. *Trial Update on ACRIN 6677 / RTOG 0625*. Committee member and **Trial PI**, ACRIN 2011 Fall meeting, Arlington, VA, September 23, 2011.

4. *Trial Update on ACRIN 6686 / RTOG 0825*. Committee member and **Trial PI**, ACRIN 2011 Fall meeting, Arlington, VA, September 23, 2011.

5. *An Update on Pseudoprogression Found in Patients with High-grade Gliomas Treated with PPX plus Temozolomide in BrUOG 223.* **Invited presentation** to BrUOG 244 investigators at Society of Neurooncology Annual Meeting, Washington, DC, November 16, 2012.

6. *DSC Perfusion Physics: Practical Technical and Clinical Considerations for Concentration Measurements in Tissues*. **Invited faculty***,* ASFNR American Society of Functional Neuroradiology 7th Annual Meeting, Charleston, SC, March 11, 2013.

7. *Recent Advances in DSC-MRI: Leakage Correction and Percent Signal Recovery Methods*. **Invited faculty***,* ASFNR American Society of Functional Neuroradiology 7th Annual Meeting, Charleston, SC, March 11, 2013.

8. *Quantitative DSC-MRI of Brain Tumors: Practical Technical and Clinical Considerations* (Radiology Grand Rounds lecture) and *Neuroradiology Case Review* (Presentation of teaching cases to Radiology residents). **Visiting Professor**, Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, August 20, 2013.

9. *Trial Update on ECOG-ACRIN E3613*. Committee member and **Trial PI** (Imaging), ECOG-ACRIN 2013 Fall meeting, Hollywood, FL, November 15, 2013.

10. *Trial Update on ACRIN 6677 / RTOG 0625*. Committee member and **Trial PI**, ECOG-ACRIN 2013 Fall meeting, Hollywood, FL, November 16, 2013.

11. *Trial Update on ACRIN 6686 / RTOG 0825*. Committee member and **Trial PI**, ECOG-ACRIN 2013 Fall meeting, Hollywood, FL, November 16, 2013.

12. *Quantitative DSC-MRI of Brain Tumors: Practical Technical and Clinical Considerations* (Radiology Grand Rounds lecture); *Susceptibility Contrast and Diffusion-Weighted MRI Techniques: Applications to Neuroimaging* (Resident Noon Conference lecture) and *Neuroradiology Case Review* (Presentation of teaching cases to Radiology residents). **Visiting Professor**, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, January 14-15, 2014.

13. *DSC Perfusion Physics: Practical Technical and Clinical Considerations for Concentration Measurements in Tissues*. **Invited faculty***,* ASFNR American Society of Functional Neuroradiology 8th Annual Meeting, Miami, FL, February 17, 2014.

14. *Pitfalls in DSC-MRI: Leakage Correction or Not?* **Invited faculty***,* ASFNR American Society of Functional Neuroradiology 8th Annual Meeting, Miami, FL, February 17, 2014.

15. *MR Perfusion Clinical Practice Standards: DSC-MRI Acquisition and Post-Processing*. **Invited faculty***,* ASFNR American Society of Functional Neuroradiology 8th Annual Meeting, Miami, FL, February 17, 2014.

16. *Does T2/FLAIR Improve on the Assessment of Response to Therapy? Results from ACRIN 6677/RTOG 0625*. **Invited presentation***,* Meeting of the RANO study group at ASCO 2014, Chicago, IL, May 30, 2014.

17. *Trial Update on ACRIN 6677 / RTOG 0625*. Committee member and **Trial PI**, ECOG-ACRIN 2014 Fall meeting, Orlando, FL, November 15, 2014.

18. *Trial Update on ACRIN 6686 / RTOG 0825*. Committee member and **Trial PI**, ECOG-ACRIN 2014 Fall meeting, Orlando, FL, November 15, 2014.

19. *DSC Perfusion Physics and Leakage Correction: Practical Technical and Clinical Considerations for Concentration Measurements in Tissues*. **Invited faculty**, ASFNR American Society of Functional Neuroradiology 9th Annual Meeting, Tucson, AZ, March 18, 2015.

20. *DSC-MRI and the Identification of Tumor Recurrence in the Setting of Pseudoprogression and Pseudoresponse*. **Invited faculty**, ASFNR American Society of Functional Neuroradiology 9th Annual Meeting, Tucson, AZ, March 18, 2015.

21. *Assessing Treatment Response of Gliomas with DSC-MRI and the Need for Standardization in Clinical Trials*. **Invited faculty**, SNO Society of Neuro-Oncology 20th Annual Meeting, San Antonio, TX, November 22, 2015.

22. *DSC Perfusion Physics and Leakage Correction: Practical Technical and Clinical Considerations*. **Invited faculty**, ASFNR American Society of Functional Neuroradiology 10th Annual Meeting, Austin, TX, February 29, 2016.

23. *Trial Update on ACRIN 6677 / RTOG 0625, ACRIN 6686 / RTOG 0825, and Concept EAF151*. Presented to the ECOG-ACRIN (Legacy ACRIN) Head/Neck/Neuro Committee (Committee member and **Trial PI**), ECOG-ACRIN 2016 Spring meeting, Boston, MA, May 13, 2016.

24. *Trial Update on Concept EAF151*. **Invited presentation** to the Brain Tumor Working Group, ECOG-ACRIN 2016 Spring meeting, Boston, MA, May 13, 2016.

25. *Assessing Treatment Response of Gliomas with DSC-MRI and the Need for Standardization in Clinical Trials*. **Invited presentation (SAM session)**, ASNR American Society of Neuroradiology 54th Annual Meeting, Washington, DC, May 24, 2016.

26. *Trial Update on ACRIN 6677 / RTOG 0625, ACRIN 6686 / RTOG 0825, and Concept EAF151*. Presented to the ECOG-ACRIN (Legacy ACRIN) Head/Neck/Neuro Committee (Committee member and **Trial PI**), ECOG-ACRIN 2016 Fall meeting, Orlando, FL, November 11, 2016.

27. *Trial Update on Concept EAF151*. **Invited presentation** to the Brain Tumor Working Group, ECOG-ACRIN 2016 Fall meeting, Orlando, FL, November 12, 2016.

28. *Evidence-Based Best Practices for Clinical DSC-MRI*. **Invited presentation**, ASNR American Society of Neuroradiology 55th Annual Meeting, Long Beach, CA, April 25, 2017.

29. *Trial Update on ACRIN 6677 / RTOG 0625, ACRIN 6686 / RTOG 0825, and Trial EAF151*. Presented to the ECOG-ACRIN (Legacy ACRIN) Head/Neck/Neuro Committee (Committee member and **Trial PI**), ECOG-ACRIN 2017 Spring meeting, Washington, DC, May 5, 2017.

30. *Trial Update on Concept EAF151*. **Invited presentation** to the Brain Tumor Working Group, ECOG-ACRIN 2017 Spring meeting, Washington, DC, May 5, 2017.

31. *Streamlining Clinical Trials to Accelerate Brain Tumor Drug Development*. **Invited participant** in a roundtable research discussion sponsored by the National Brain Tumor Society, Washington, DC, June 28, 2017.

32. *DSC Perfusion Physics and Leakage Correction: Practical Technical and Clinical Considerations*. **Invited faculty***,* ASFNR American Society of Functional Neuroradiology 11th Annual Meeting, Portland, OR, October 9, 2017.

33. *Assessing Treatment Response of Gliomas with DSC-MRI*. **Invited faculty***,* ASFNR American Society of Functional Neuroradiology 11th Annual Meeting, Portland, OR, October 9, 2017.

34. *Trial Update on ACRIN 6677 / RTOG 0625, ACRIN 6686 / RTOG 0825, and Trial EAF151*. Presented to the ECOG-ACRIN (Legacy ACRIN) Head/Neck/Neuro Committee (Committee member and **Trial PI**), ECOG-ACRIN 2017 Fall meeting, Orlando, FL, October 27, 2017.

35. *Trial Update on Concept EAF151*. **Invited presentation** to the Brain Tumor Working Group, ECOG-ACRIN 2017 Fall meeting, Orlando, FL, October 27, 2017.

36. *DSC-MRI: Efforts Towards Standardization and Use Cases for CBV and Other Markers in Neuro-oncology Clinical Trials*. **Invited presentation** to the National Cancer Institute Clinical Imaging Steering Committee, *Improving Brain Tumor Characterization with Advanced Neuroimaging Methods Workshop*, Shady Grove (Rockville), MD, April 18-19, 2018.

37. *Overview of EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma*. **Invited presentation** at the RA Education Symposium, ECOG-ACRIN 2018 Spring meeting, Chicago, IL, May 4, 2018.

38. *Trial Update on ACRIN 6677 / RTOG 0625, ACRIN 6686 / RTOG 0825, and Trial EAF151*. Presented to the ECOG-ACRIN (Legacy ACRIN) Brain/Neuro Committee (Committee member and **Trial PI**), ECOG-ACRIN 2018 Spring meeting, Chicago, IL, May 5, 2018.

39. *Trial Update on Concept EAF151*. **Invited presentation** to the Brain Tumor Working Group, ECOG-ACRIN 2018 Spring meeting, Chicago, IL, May 5, 2018.

40. *DSC-MRI: Application to Clinical Trials and the Need for Standardization*. **Invited faculty***,* presented at ASFNR American Society of Functional Neuroradiology 12th Annual Meeting, San Diego, CA, October 15, 2018.

41. *Overview of EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma*. **Invited presentation** at the Clinical Research Associate Symposium, ECOG-ACRIN 2019 Fall meeting, Ft. Lauderdale, FL, October 26, 2018.

42. *Overview of EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma*. **Invited presentation** at the Oncology Nursing Committee Symposium, ECOG-ACRIN 2019 Fall meeting, Ft. Lauderdale, FL, October 26, 2018.

43. *Trial Update on ACRIN 6677 / RTOG 0625, ACRIN 6686 / RTOG 0825, and Trial EAF151*. Presented to the ECOG-ACRIN (Legacy ACRIN) Brain/Neuro Committee (Committee member and **Trial PI**), ECOG-ACRIN 2018 Fall meeting, Ft. Lauderdale, FL, October 26, 2018.

44. *Clinical Trials and Translational Research Advisory Committee Ad hoc Working Group on Glioblastoma.* **Invited participant** in a subgroup exploring GBM Clinical Trials Driven by Molecular Pharmacodynamics and Imaging, sponsored by the NCI, Washington, DC, January 14, 2019.

45. *Trial Update on ACRIN 6677 / RTOG 0625, ACRIN 6686 / RTOG 0825, and Trial EAF151*. Presented to the ECOG-ACRIN (Legacy ACRIN) Brain/Neuro Committee (Committee member and **Trial PI**), ECOG-ACRIN 2019 Spring meeting, Boston, MA, May 3, 2019.

46. *An Update on Standardization of DSC-MRI Methodology for Use in Multi-center Clinical Trials.* **Invited presentation***,* Meeting of the RANO study group at ASCO 2019, Chicago, IL, May 31, 2019.

INTERNATIONAL

1. *DSC Concentration Measurements in Tissues with Practical Technical and Clinical Considerations.* **Invited faculty**, ISMRM Scientific Workshop on Perfusion MRI, Amsterdam, The Netherlands, October 12, 2012.

2. *DSC-MRI and Its Role in Distinguishing Tumor Recurrences from Pseudoprogression and Pseudoresponse*. **Invited presentation***,* ASNR American Society of Neuroradiology 52nd Annual Meeting, Montreal, Quebec, Canada, May 20, 2014.

3. *DSC-MRI Fundamentals and Applications to Brain Tumors Including Assessment of Treatment Response and the Need for Standardization in Clinical Trials*. **Invited presentation (SAM session)**, ENRS Eastern Neuroradiological Society 28th Annual Meeting, Quebec City, Quebec, Canada, August 11, 2016.

4. *Evidence-Based Best Acquisition Protocols for Clinical DSC-MRI with an Emphasis on Neuro-oncology Trials*. **Invited presentation in the educational course *Basic Perfusion*,** ISMRM International Society of Magnetic Resonance in Medicine 27th Annual Meeting, Montreal, Quebec, Canada, May 12, 2019.

SESSION SUPERVISION AT NATIONAL CONFERENCES

1. *Adult Brain: Cerebrovascular Occlusive Disease I (Scientific Papers)*, **Co-moderator.** ASNR American Society of Neuroradiology 45th Annual Meeting, Chicago, IL, June 13, 2007.

2. *Interventional: Thrombolysis/Stroke (Scientific Papers)*, **Co-moderator.** ASNR American Society of Neuroradiology 49th Annual Meeting, Seattle, WA, June 7, 2011.

3. *Physics Basic I (Invited Presentations)*, **Moderator.** ASFNR American Society of Functional Neuroradiology 8th Annual Meeting, Miami, FL, February 17, 2014.

4. *Adult Brain*, **Co-chair, Program Committee.** ENRS Eastern Neuroradiological Society 29th Annual Meeting, Toronto, Ontario, Canada, August 24, 2017.

5. *ASFNR Programming: Perfusion Imaging for the Clinician (Invited Presentations)*, **Co-moderator.** ASNR American Society of Neuroradiology 57th Annual Meeting, Boston, MA, May 20, 2019.

GRANTS

1. *MRI Contrast Agent Methods to Assess Tumor Angiogenesis* (RO1 CA082500)
   NIH / National Cancer Institute
   Principal Investigator: Kathleen Schmainda, Ph.D.
   Consultant
   2003 –2007

2. *Diffusion-tensor and perfusion-weighted MRI for improved detection of early cerebrovascular white matter injury in patients with hypertension*
   Department of Diagnostic Imaging (RIH) Seed Grant ($15,000)
   Principal Investigator
   2005

3. *Utilization of MR Perfusion Imaging as a Screening Tool to Assess the Risk of Stroke in Asymptomatic Patients with Sickle Cell Disease: A Feasibility Study*
   Department of Diagnostic Imaging (RIH) Seed Grant ($15,000)

Co-Principal Investigator
2006

4. *Quantification of Blood-Brain Barrier Permeability to Water with MRI: Validation of Intravascular Contrast Agent Tecnique in Transgenic Mouse Models of Altered Blood-Brain Barrier Permeability and Application to Human Neurodegenerative Disease*
Department of Diagnostic Imaging (RIH) Seed Grant ($15,000)
Principal Investigator
2009

5. *Magnetic nanoparticle hyperthermia of glioblastoma with real-time MRI monitoring*
Department of Diagnostic Imaging (RIH) Seed Grant ($15,000)
Co-Principal Investigator
2010

6. *Toward Multi-Center MR Brain Perfusion* (RO1 NS060918)
NIH / National Institute of Neurological Disorders and Stroke
Principal Investigator: Steven Stufflebeam, M.D., Ph.D.
Consultant
2012-2015

PARTICIPATION IN NIH/NCI-FUNDED TRIALS

1.	2011-Present	ACRIN **Principal Investigator**, ACRIN 6677/RTOG 0625: *A Randomized Phase II Trial of Bevacizumab with Irinotecan or Bevacizumab with Temozolomide in Recurrent Glioblastoma*. Funded by NCI U01-CA080098 and U01-CA079778.
2.	2011-Present	ACRIN **Principal Investigator**, ACRIN 6686/RTOG 0825: *Phase III Double Blind Placebo-Controlled trial of conventional concurrent chemoradiation and Adjuvant Temozolomide plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma*. Funded by NCI U01-CA080098 and Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP).
3.	2017-Present	**Principal Investigator**, ECOG-ACRIN EAF151: *Change in Relative Cerebral Blood Volume as a Predictive Biomarker for Response to Bevacizumab in Patients with Recurrent Glioblastoma.* Funded by NCI U01-CA180820.
4.	2017-Present	**Co-Principal Investigator** (with Schmainda KM [MCW], Hu L [Mayo Scottsdale], Quarles CC [Barrow Neurological Institute]): *Multi-site Validation and Application of a Consensus DSC-MRI Protocol*. Funded by NCI R01-CA221938-01.

PARTICIPATION IN OTHER FUNDED TRIALS

1. 2008-2009 **Co-Investigator** (Jeffrey Rogg, PI), *A multicenter, randomized, double-blind, crossover, phase III study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the central nervous system*
Funded by Bayer Pharmaceuticals, Inc.

2. 2011-2012 **Co-Investigator** (Jeffrey Rogg, PI), *GEMSAV: Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of contrast-enhanced magnetic resonance angiography (MRA) after a single intravenous injection of 0.1 mmol/kg gadobutrol in subjects with known or suspected vascular disease of the supra-aortic vessels*
Funded by Bayer Pharmaceuticals, Inc.

3. 2011-2014 **Central Neuroradiologist** (Howard Safran, PI), *PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244*
Funded by Cell Therapeutics, Inc.

4. 2013-present **Co-Investigator** (Ott BR, PI), *221AD103: A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharacokinetics and Pharmacodynamics of BIIB037 in Subjects with Prodromal or Mild Alzheimer's Disease*.
Funded by Biogen.

5. 2016-2018 **Co-Investigator** (Rogg JM, PI), *GDX-44-004: Phase IIB P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)*.
Funded by Guerbet Pharmaceuticals.

GRANTS SUBMITTED, APPROVED FOR FUNDING

1. February 2019 **Co-investigator** (Kathleen Schmainda, PI), *Quantitative (Perfusion and Diffusion) MRI Biomarkers to Measure Glioma Response*. Submitted to NIH grant mechanism: PAR-17-129 (UO1) Quantitative Imaging Tools and Methods for Cancer Response Assessment.
5% effort x 3 years (7/2020–6/2023)

2. February 2019 **Co-investigator** (Lori Daiello, PI), *Blood-brain Barrier Disruption as a Biomarker for Perioperative Neurocognitive Disorders: Cognitive Recovery After Elective Surgery (CREATES) study.* Submitted to NIH grant mechanism: PAR-18-029 (RO1)

Clarifying the Relationship between Delirium and Alzheimer's Disease and Related Dementias.
10% effort years 1–3, 5% effort years 4–5

GRANTS SUBMITTED, AWAITING DECISION

1. February 2019 **Co-investigator** (Steve Toms, PI), *The Role of Epigenetic Regulation in Human Glioma: Non-Coding RNA and RNA Methylation.* Re-submitted to Warren Alpert Foundation Prize.
5% effort x 5 years

2. March 2019 **Co-investigator** (Karen Furie, PI), *Chagas Cog: Cognitive Outcomes in Chagas Disease*. R01 re-submission.
2-3% effort x 5 years

3. June 2019 **Co-investigator** (Jayashree Kalpathy-Cramer, PI), *Clinical and Translational Applications of Quantitative Imaging Tools in Brain Tumors.* Submitted to NIH grant mechanism: PAR-18-919 (R01) Quantitative Imaging Tools and Methods for Cancer Response Assessment.
10% effort x 5 years

UNIVERSITY TEACHING, ADVISING AND MENTORING ROLES

TEACHING ASSIGNMENTS

RAD 6290: Clerkship in Diagnostic Radiology
The Warren Alpert Medical School of Brown University
2002-Present
Review of neuroradiology teaching cases with medical students in order to familiarize them with the breadth of neurologic imaging techniques and applications.

RAD 6330: Cross Sectional Imaging in Clinical Medicine
The Warren Alpert Medical School of Brown University
2002-Present
Review of neuroradiology cases performed at Rhode Island Hospital while reading out with the radiology residents.

RAD 6360: Neuroradiology
The Warren Alpert Medical School of Brown University
2011-Present
Co-director (with Jeffrey Rogg, M.D.) of a one-month neuroradiology elective. The goal of this elective is to expose the medical student to non-invasive and invasive forms of neuroradiology and reinforce the student's knowledge of neuroanatomy and neuropathology.

PH 2620 Selected Topics in Molecular Biophysics, **lecturer** (*Susceptibility Contrast in MRI Applications*)
Brown University Graduate School of Physics

Course Director: Jay Tang, Ph.D.
Lecture date: 5/1/2012.

BIOL 1200 Protein Biophysics and Structural Biology, **lecturer** (*Susceptibility Contrast in MRI Applications*)
Brown University Graduate School of Biology
Course Director: Wolfgang Peti, Ph.D.
Lecture dates: 4/30/2013 and 4/29/2014.

BIOL 3652 Integrated Medical Science II: Brain Sciences, **Group leader** for "Small Groups" teaching sessions for 1st year Brown medical students taking the required Brain Sciences section.
The Warren Alpert Medical School of Brown University (Basic Science)
2011-present
Recent session dates: 2/8/2017, 3/1/2017, 2/2/2018, 2/12/2018.

BIOL 3652 Integrated Medical Science II: Brain Sciences, **lecturer** (*Advanced MRI Techniques in Neuroradiology*)
The Warren Alpert Medical School of Brown University (Basic Science)
Lecture date: February 2012.

BIOL 6674 Introduction to Diagnostic Imaging, **lecturer** (*Advanced Neuro MRI Applications* and *Neuroradiology Principles, Common Imaging Applications, and Case Review*)
The Warren Alpert Medical School of Brown University
Course Director: Don Yoo, M.D.
2016-present
Lecture dates: 5/10/2016, 11/8/2016.

CNS-5325 Clerkship in Neurology, **Director** of the neuroradiology component and **lecturer** (*Introduction to Neuroradiology: Basic Principles, Common Imaging Indications, and Case Review*) to all 3rd-year medical students taking this required elective.
The Warren Alpert Medical School of Brown University
2015-present
Lecture dates: 8/12/2015, 11/11/2015, 2/10/2016, 6/1/2016, 8/3/2016, 11/2/2016, 2/1/2017, 5/31/2017, 8/2/2017, 11/1/2017, 1/31/2018, 5/30/2018, 8/1/2018, 10/31/2018, 1/30/2019, 6/5/2019.

Radiology Lecture Series for Primary Care-Population Medicine Program Longitudinal Integrated Clerkship (LIC), **lecturer** (*Introduction to Neuroradiology: Basic Principles, Common Imaging Indications, and Case Review*).
The Warren Alpert Medical School of Brown University
Course Director: Don Yoo, M.D.
2016-present

ADVISING ROLES

UNDERGRADUATE THESIS COMMITTEES

2017-2018 Ashley Aldridge (Bachelor of Arts with Honors)

Program in Liberal Medical Education, concentration in Health and Human Biology, Brown University

Second Reader (Wael Asaad, thesis advisor)

Thesis: Factors Contributing to Brain Shift in Deep Brain Stimulation Surgery

GRADUATE THESIS COMMITTEES

2017-present Menghan Hu (Ph.D. candidate)

Department of Biostatistics, Brown University School of Public Health

Member of Thesis Committee (Ani Eloyan, thesis advisor)

Thesis: Statistical Methods for Longitudinal Magnetic Resonance Imaging for Multiple Sclerosis

RESEARCH SUPERVISION AND MENTORING ROLES

Matthew Lee, Medical student, Warren Alpert Medical School.

Dates of mentorship: 2017-Present.

Role: Research advisor and career mentor during medical school; faculty advisor during a one-month independent study period.

Published abstracts:

Lee et al. Utility of Percent Signal Recovery and Average Baseline Signal in DSC-MRI Optimized for rCBV Measurement for Differentiation of GBM, Metastasis, Lymphoma and Meningioma. Platform presentation at ASNR American Society of Neuroradiology 56th Annual Meeting, Vancouver, BC, June 4, 2018, presentation O-35.

Submitted papers:

Lee et al. Utility of Percent Signal Recovery and Average Baseline Signal in DSC-MRI Optimized for rCBV Measurement for Differentiation of GBM, Metastasis, Lymphoma and Meningioma. Submitted to AJNR Am J Neuroradiol, March 2019.

HOSPITAL TEACHING, ADVISING AND MENTORING ROLES

TEACHING ASSIGNMENTS

Weekly neuro-oncology tumor board, Rhode Island Hospital, **primary covering neuroradiologist** (Review all imaging studies at each conference)

Weekly neurosurgery grand rounds, Rhode Island Hospital, **shared coverage** (Review all imaging studies at each conference)

Weekly neurology conference (neuroradiology case review), Rhode Island Hospital, **shared coverage** (Review all imaging studies at each conference)

Twice/month pediatric neuro-oncology tumor board, Rhode Island Hospital, **shared coverage** (Review all imaging studies at each conference)

Twice/month head & neck tumor board, Rhode Island Hospital, **shared coverage** (Review all imaging studies at each conference)

Monthly comprehensive epilepsy case conference, Rhode Island Hospital, **shared coverage** (Review all imaging studies at each conference)

Radiology Residents: Neuroradiology Case Conference, Rhode Island Hospital (**Attend and participate**, 1/month)

Radiology Residents: Imaging Conference, Rhode Island Hospital (**Attend and participate**, 2/month)

Radiology Residents: approx. 10 **didactic teaching and case review** sessions per year

Radiology Residents—MRI physics (2 lectures/year)
Developed the MR physics curriculum for the Department of Diagnostic Imaging residents dealing with pulse sequences, image characteristics, image artifacts, and special acquisition methods.

Medicine Residents—Introduction to Neuroradiology and Neuroradiology Services at RIH (1 lecture/year)

RESEARCH SUPERVISION AND MENTORING ROLES

Marc Goldman, Resident, Department of Neurosurgery, Warren Alpert Medical School.

Dates of mentorship: 2004-2008.

Role: Research advisor during residency.

Published abstracts:

Goldman et al. The utility of apparent diffusion coefficient for predicting response of non-small cell lung cancer brain metastases to stereotactic radiosurgery. American Society of Neuroradiology 44th Annual Meeting. San Diego, CA, 2006.

Goldman et al. The utility of apparent diffusion coefficient for predicting response of brain metastases to gamma knife radiosurgery. 13th International Meeting of the Leksell Gamma Knife Society, Seoul, Korea, May 21-25, 2006.

Goldman et al. Initial tumor volume decrease is not predictive of therapeutic response to gamma knife radiosurgery for intracranial breast and non-small cell lung metastases. 13th International Meeting of the Leksell Gamma Knife Society, Seoul, Korea, May 21-25, 2006

Published papers:

Goldman M et al. The Utility of Apparent Diffusion Coefficient in Predicting the Outcome of Gamma Knife Treated Brain Metastases Prior to Changes in Tumor Volume: a Preliminary Study. J Neurosurg 2006 Dec; 105(Suppl):175-182.

William Mehan, Resident, Department of Diagnostic Imaging, Warren Alpert Medical School.

Dates of mentorship: 2010-2012.

Role: Research advisor during residency.

Published abstracts:

Mehan et al. What Is the Added Value of CTP above CTA in Decision Making for Intra-Arterial Stroke Therapy? RSNA 96th Scientific Assembly, 2010, Presentation SSC12-05.

Published papers:

Boxerman et al. Clinical Stroke Penumbra: Use of NIH Stroke Scale as a Surrogate for CT Perfusion in Patient Triage for Intra-arterial MCA Stroke Therapy. AJNR Am J Neuroradiol 2012 33(10):1893-900.

Marissa Blitstein, Resident, Department of Diagnostic Imaging, Warren Alpert Medical School.

Dates of mentorship: 2010-2012.

Role: Research advisor during residency.

Published abstracts:

Blitstein et al. The Role of Longitudinal Perfusion-Weighted MRI Measures in Distinguishing Tumor Recurrence from Pseudoprogression in a Cohort of Patients with High-Grade Gliomas Receiving Radiation Therapy (IMRT), Temozolomide (TMZ) and Paclitaxel Poliglumex (PPX). American Society of Neuroradiology 49th Annual Meeting, Seattle, June 2011, Presentation 539.

Blitstein et al. Clinical correlation and significance of MRI findings in Chiari I malformation. American Society of Neuroradiology 49th Annual Meeting, Seattle, June 2011, Presentation 485.

Deepak Raghavan, Resident, Department of Diagnostic Imaging, Warren Alpert Medical School.

Dates of mentorship: 2010-2012.

Role: Research advisor during residency.

Published papers:

Raghavan et al. Glioblastoma Multiforme: Utilization of Advanced MRI Techniques for Preoperative Planning. Med Health RI 2012 Feb;95(2):42-3.

Raghavan et al. Radiation Necrosis of a High-Grade Glioma. Med Health RI 2012 May;95(5):159-60.

Joseph Farnam, Resident, Department of Diagnostic Imaging, Warren Alpert Medical School.

Dates of mentorship: 2013.

Role: Research advisor during residency.

Published abstracts:

Farnam et al. Extreme Pseudoprogression on MRI of High-grade Gliomas Treated

with Paclitaxel Poliglumex: Comparison with Conventional Pseudoprogression and True Tumor Progression. American Society of Neuroradiology 51st Annual Meeting, San Diego, May 2013, presentation as an education exhibit (EdE-16).

Elizabeth Dibble, Resident, Department of Diagnostic Imaging, Warren Alpert Medical School.

Dates of mentorship: 2014-2016.

Role: Research advisor during residency.

Published abstracts:

Dibble et al. Toxoplasmosis versus Lymphoma: Cerebral Lesion Characterization Using Dynamic Susceptibility Contrast MRI and Relative Cerebral Blood Volume Estimates. American Society of Neuroradiology 53rd Annual Meeting, Chicago, April 2015, oral presentation O-173.

Published papers:

Dibble et al. Toxoplasmosis versus Lymphoma: Cerebral Lesion Characterization Using DSC-MRI Revisited. Clin Neurol Neurosurg. 2017 Jan;152:84-89.

Amanda Baker, Resident, Department of Diagnostic Imaging, Warren Alpert Medical School.

Dates of mentorship: 2016-Present.

Role: Research advisor during residency.

Published abstracts:

Baker et al. Radiographically Occult Tethered Cord in Pediatric and Adult Patients. Platform presentation at ASNR American Society of Neuroradiology 56th Annual Meeting, Vancouver, BC, June 5, 2018, presentation O-208.

Matthew Stib, Resident, Department of Diagnostic Imaging, Warren Alpert Medical School.

Dates of mentorship: 2018-Present.

Role: Research mentor during residency.

Published abstracts:

Stib et al. Localizing Large Vessel Occlusions on CT Angiography Using a 3-D Deep Learning Model. Poster presentation at International Stroke Conference 2019, Honolulu, HI.

Stib et al. Deep Learning in Emergent Large Vessel Occlusion Detection using Maximum Intensity Projections via CT Angiography. Poster presentation at SIIM Machine Learning Conference, San Francisco, September 2018.